{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-24-000225","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.718751+00:00","generated_at":"2026-06-03T03:28:49.692069+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KORU Medical Q1 revenue up 11% to $8.2M; gross margin expands 620bps to 62.3%","bullets":["Net revenues of $8.2M, +10.9% YoY; Core business grew 13.6%, driven by 63% International increase.","Gross margin 62.3% vs 56.1% YoY, aided by outsourced manufacturing and US site consolidation.","Net loss narrowed to $1.9M ($0.04/share) from $2.4M; Adj EBITDA loss improved to $0.9M.","Reaffirmed FY2024 revenue guidance of $31.2-32.2M (10-13% growth); gross margin 59-61% expected.","Added a novel oncology therapy collaboration, bringing total to 16, with 3 YTD."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-24-000225","json":"https://secwatch.observer/filing/0001161697-24-000225.json","markdown":"https://secwatch.observer/filing/0001161697-24-000225.md","text":"https://secwatch.observer/filing/0001161697-24-000225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/0001161697-24-000225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:28:49.692069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1eeca9e786b7140e6bca88592b6038c8b1f16458","claim":"KORU Medical Systems, Inc. reported full year 2024 results: revenue $31.2 million to $32.2 million. Guidance reaffirmed.","evidence_excerpt":"Reaffirmed full year 2024 revenue guidance of $31.2 million to $32.2 million, representing growth of 10% to 13% over the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/0001161697-24-000225-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$31.2 million to $32.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"901f0226597353409163648b4b29046c1a2c55c2","claim":"KORU Medical Systems, Inc. reported first quarter ended March 31, 2024 results: revenue 8.2 million, net income net loss of $1.9 million, EPS $(0.04) per diluted share.","evidence_excerpt":"large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights ● First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenues ● Core business (U.S. and International) growth of 14% over the prior year, driven by overall SCIg market","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/0001161697-24-000225-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"8.2 million"},{"label":"Net income","value":"net loss of $1.9 million"},{"label":"EPS","value":"$(0.04) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}